I
Ilaria Marchetti
Researcher at University of Milan
Publications - 6
Citations - 298
Ilaria Marchetti is an academic researcher from University of Milan. The author has contributed to research in topics: Randomized controlled trial & Clinical trial. The author has an hindex of 5, co-authored 6 publications receiving 292 citations.
Papers
More filters
Journal ArticleDOI
Clinical ability of Heidelberg retinal tomograph examination to detect glaucomatous visual field changes.
Stefano Miglior,Marta Casula,Magda Guareschi,Ilaria Marchetti,Michele Iester,Nicola Orzalesi +5 more
TL;DR: In this paper, the agreement between the visual field-based and HRT definition of glaucoma was fair to poor, with a κ statistic of between 0.48 and 0.28.
Journal ArticleDOI
Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice
Luca Rossetti,Ilaria Marchetti,Nicola Orzalesi,N. Scorpiglione,Valter Torri,Alessandro Liberati +5 more
TL;DR: Practical ophthalmologists should be aware that the effectiveness of pressure-lowering agents in the treatment of primary open angle glaucoma is still to be determined and that the vast majority of published trials are not appropriate to guide clinical practice.
Journal ArticleDOI
Heart rate variability to monitor performance in elite athletes: Criticalities and avoidable pitfalls
Daniela Lucini,Ilaria Marchetti,Antonio Spataro,Mara Malacarne,Manuela Benzi,Stefano Tamorri,Roberto Sala,Massimo Pagani +7 more
TL;DR: Caution must be payed when assessing HRV with non-ECG wearable devices and ensuring that respiratory rate is higher than 10 breath/min are both prerequisites for a more reliable analysis of HRV particularly in athletes.
Journal ArticleDOI
Randomized clinical trials on medical treatment of glaucoma: Are they appropriate to guide clinical practice?
Luca Rossetti,Ilaria Marchetti,Nicola Orzalesi,Nicola Scorpigilione,Valter Torri,Alessandro Liberati +5 more
TL;DR: Practical ophthalmologists should be aware that the effectiveness of pressure-lowering agents in the treatment of primary open angle glaucoma is still to be determined and that the vast majority of published trials are not appropriate to guide clinical practice.
Is proper methodology associated with the use of a clinically relevant outcome measure? The case of randomized clinical trials on medical treatment of open-angle glaucoma.
TL;DR: It is found that those studies adopting a double-masked design and those not excluding patients after randomization followed patients for longer periods of time and assessed treatment effectiveness using a clinically relevant outcome compared to other studies.